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Background: The North American Opiate Medication Initiative (NAOMI) clinical trial compared the effectiveness of
injectable diacetylmorphine (DAM) or hydromorphone (HDM) to oral methadone maintenance treatment (MMT).
This study aimed to determine participants’ perceptions of treatment delivered in NAOMI.
Methods: A qualitative sub-study was conducted with 29 participants (12 female): 18 (62.1%) received injectable
DAM or HDM and 11 (37.9%) received MMT. A phenomenological theoretical framework was used. Semi-structured
interviews were audio-recorded and transcribed verbatim. A thematic analysis was used over successive phases and
was driven by the semantic meanings of the data.
Results: Participants receiving injectable medications suggested that the supervised delivery model was stringent
but provided valuable stability to their lives. Females discussed the adjustment required for the clinical setting,
while males focused on the challenging clinic schedule and its impact on employment abilities. Participants
receiving MMT described disappointment with being randomized to this treatment; however, positive aspects,
including the quick titration time and availability of auxiliary services, were also discussed.
Conclusion: Treatment with injectable DAM (or HDM) is preferred by participants and considered effective in
reducing the burden of opioid dependency. Engaging patients in research regarding their perceptions of treatment
provides a comprehensive assessment of treatment needs and barriers.
Clinical trial registration: NCT00175357
Keywords: Opioid dependency, Diacetylmorphine, Injectable, Oral methadone, Opioid maintenance treatment,
Qualitative methodsBackground
Opioid dependence is a chronic, relapsing disease that
can be fatal if untreated [1]. Abstinence-based therapies,
a first-line treatment choice in many countries, have been
shown to successfully treat patients who have stable hous-
ing, family support, and personal motivation (e.g., readi-
ness for change) [2]. However, the marginalization that
often accompanies long-term opioid dependence [3] is* Correspondence: eugenia@cheos.ubc.ca
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article, unless otherwise stated.associated with a decrease in the effectiveness of
abstinence-based treatments, with less than 30 percent
of patients remaining abstinent after one year [4]. Opioid
substitution-based therapies, mainly oral methadone main-
tenance treatment (MMT), are considered the most effect-
ive options for the treatment of opioid dependence [2].
Although MMT is effective for many patients [5,6], it
is estimated that 15–25 percent of the most severely af-
fected individuals with opioid dependence are not reached
or retained by MMT [7,8]. These individuals do not stay
in MMT for very long, or they continue to use illicit
opioids while in treatment [9,10]. Studies in Europe and
Canada have demonstrated that supervised, medically
prescribed heroin (i.e., diacetylmorphine, [DAM]) is anCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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viduals not benefitting sufficiently from available treat-
ments [11]. The clinical trial conducted in Canada—the
North American Opiate Medication Initiative (NAOMI)—
demonstrated the effectiveness of the supervised model
of medically prescribed injectable DAM compared to
oral methadone [12]. Participants randomized to inject-
able treatments in this study achieved a better clinical re-
sponse and higher retention to treatment at 12 months,
compared to those randomized to oral treatment [12].
Under this model, DAM is dispensed and self-
administered by injection (or swallowed or inhaled in
some clinics) under supervision in specially designed
clinics. The rationale behind this model is that by pro-
viding pharmaceutical-grade heroin in the presence of
health care providers, individuals not benefitting from
other treatments are more likely to be attracted and
retained in treatment. They are protected from com-
mon harms (e.g., fatal overdose and infectious disease
transmission), since the dose and purity are controlled
on site. This treatment also provides an opportunity to
reduce illegal activities often arising from heroin ad-
diction, by delivering medical and psychosocial sup-
port services as well.
Since the medication must be delivered on clinic
premises (i.e., no ‘take-home’ doses), participants attend
the clinic at least twice daily and undergo pre-intake
(15 minutes) and post-intake assessments (30 minutes).
Thus, providing injectable DAM might be a very demand-
ing model for patients and could affect compliance. More
generally, patient adherence to life-saving treatment for
conditions such as diabetes, even when they can take the
medications with them, has an average nonadherence
rate of 24.8 percent [13]. A social researcher on addic-
tions has criticized this aspect of the supervised model
and suggested that qualitative research is needed to help
understand how and why heroin prescription works so
effectively [14]. These questions reinforce the need to in-
clude an evaluation of the intervention’s process and out-
comes by the patients themselves to guide clinical decisions,
as part of a patient-centered model of care [15-17].
Few studies have explored patient perceptions of inject-
able DAM treatment using structured interviews, satis-
faction measures [18,19], and qualitative data [18-22]. A
qualitative study with 21 participants and family taking
part in the Andalusian clinical trial explored the per-
ceived impact of medically prescribed DAM adminis-
tered under supervision. The study described a change
in participants’ perceptions and perceived significance
of the substance (from illicit drug to a medication) and
explored improvements in the workplace, family rela-
tions, and physical and mental health [20]. A study con-
ducted in the Netherlands provided qualitative data
from 24 participants who discussed the positive impactof having a reliable supply of DAM in improving their
daily lives by reducing or discontinuing their involve-
ment in illicit and street-based activities (e.g., drug deal-
ing, hustling, and sex work) [21].
While we assessed satisfaction with injectable and oral
treatments among NAOMI trial participants in a prior
study [18], the questions regarding why the injectable
group was more satisfied or why participants perceived
the treatment to be effective remained unanswered. The
aim of the present study was to further explore partici-
pants’ perceptions of the treatments delivered during the
trial in order to improve our understanding of the effect-
iveness of these treatments and the model of care.
Methods
The NAOMI study
NAOMI was an open-label, phase III randomized con-
trolled trial (RCT) that compared supervised injectable
DAM and oral methadone in the treatment of long-term
opioid dependence. The study was conducted in Vancouver
and Montreal, Canada, between 2005 and 2008. Partici-
pants were aged 25 or older, with at least 5 years of opioid
dependence, current daily injection of illicit opioids, a
minimum of two previous treatments for opioid depend-
ence, including at least one opioid substitution treatment
(OST) attempt, and no enrollment in OST within the
prior 6 months. A full description and discussion of the
participants’ profiles, study design, methodology, and
main results have been published elsewhere [12,23,24].
Briefly, a total of 251 individuals were randomized to re-
ceive oral methadone (n = 111), injectable DAM (n = 115),
or injectable hydromorphone (HDM) (n = 25); the latter
two on a double-blind basis. Participants administered the
injectable medications up to three times daily under the
supervision of clinic staff, and oral methadone was dis-
pensed daily. Trial treatments were provided for 12 months,
with an additional 3-month period to taper and transition
to other treatment modalities (primarily methadone). Par-
ticipants met with their study physician at least once per
month for reviewing and discussing their medication. Par-
ticipants had access on site to a comprehensive range of
psychosocial and other primary care services, including
referral to specialists and treatment for concurrent dis-
orders. The procedures followed in the trial were in ac-
cordance with the Helsinki declaration [25].
NAOMI Participants’ experiences study
Study design
The NAOMI participants’ experiences study was a quali-
tative sub-study that aimed to understand the impact of
the NAOMI trial on participants’ lives. A phenomeno-
logical theoretical framework was chosen [26]. This study
design was most appropriate for providing a description of
the meaning and significance of participants’ prior lifetime
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ing the clinical trial [26,27]. Participants eligible for this
qualitative sub-study were beyond the 12-month NAOMI
treatment period (to avoid interference with the RCT’s
primary outcome measures at the Vancouver site).
Participants were selected through stratified probability-
based sampling. Stratum included male and female gen-
der, Aboriginal and non-Aboriginal ethnicity, and oral and
injectable treatment groups. Although less commonly
used in qualitative research [28], the stratified probability-
based sampling was most appropriate to ensure that a
nonbiased and representative sample of participants
was included, improving credibility [29]. A total of 32
participants were randomly selected, representing the
stratum defined above. This sample size was directed
by the sub-study’s research questions and goal for
representativeness.
Data collection procedure
The University of British Columbia/Providence Health
Care Research Ethics Board approved the study, and all
participants provided written informed consent. Semi-
structured qualitative interviews were conducted by re-
search staff, independent of the clinical team, between
February and September 2008. The study coordinator
(JC) invited participants and explained the aims of the
qualitative sub-study. Participants received monetary com-
pensation for their time.
Interviews were held one time only with consenting
participants at the NAOMI research office, with either
the parent study coordinator (JC) or the second inter-
viewer (parent study research staff ). Both interviewers
were female and were experienced with the study popu-
lation in general. By the start of this qualitative study,
the interviewers had met with participants several times
before (every 3 months) to conduct follow-up research
interviews for the parent trial that had started 3 years
prior. Therefore, the interviewers had a contextual grasp
of the participants’ lives, and participants were familiar
with them. The research interviewers for the sub-study
received additional training on conducting semistruc-
tured interviews as well as collecting data on the topics
included in the topic guide.
A semistructured topic guide was used with an open-
ended questioning approach. Topics included: drug use
history and prior addiction treatment, situation before
NAOMI, expectations of NAOMI, situation during NA-
OMI, situation after NAOMI, and general perceptions of
the NAOMI experience. When necessary, interviewers
repeated or rephrased questions to ensure that the topics
were covered; prompting was not used. Interviews lasted
between 45 minutes and 2 hours. All interviews were
audio-recorded and transcribed verbatim by an inde-
pendent contractor.The parent study research coordinator and study in-
vestigators (EOJ, MTS) met regularly during the data
collection phase to review and discuss the data collected.
Upon completing 29 interviews, it was agreed by the
team that no new information was being gathered from
the interviews and across each stratum.
Data analysis
An inductive thematic analysis approach was used. The
thematic framework established by the researchers (EOJ,
KM, DCM, MTS) was semantic and driven by the expli-
cit meanings of the data [30]. This framework was orga-
nized according to the main topics of the semistructured
interviews. Data analysis was led by two of the authors
(EOJ, KM) over successive phases. All coding and ana-
lysis was done using NVivo software for qualitative data
analysis [31].
In the first phase, prior to any coding taking place,
EOJ and KM first read each transcript to familiarize
themselves with the data. During the second phase, ini-
tial ‘free’ codes were created based on semantic content.
The lead researchers reviewed the initial free codes to-
gether and created the following major themes during
the third phase: a) reasons for participating in NAOMI;
b) perceived impact of NAOMI treatment; c) percep-
tions of the delivery of NAOMI treatment; d) recom-
mendations; and e) experiences with ending NAOMI.
Further review and refinement of the data was done in
the next phase of analysis. The content of the major themes
was reviewed; minor themes were identified based on
predominating patterns [32].
After this phase, the researchers met to review prelim-
inary thematic maps to refine and define themes for the
objectives of the present paper. During the analysis,
comments were compared by gender (male and female),
ethnicity (Aboriginal and non-Aboriginal), and treatment
characteristics (treatment arm, retention, and response).
These characteristics were also used to identify partici-
pants’ quotes.
Results
Participants’ characteristics were representative of the
parent clinical trial (Vancouver) sample [23]: 12 (41.4%)
female and 17 (58.6%) male, Aboriginal ethnicity (27.6%),
and average age of 44. A total of 14 participants (48.3%)
received DAM, 4 (13.8%) received HDM, and 11 (37.9%)
received oral MMT. Nineteen (65.5%) participants were
considered responders, and 25 (86.2%) were retained in
treatment.
Reasons for participating in NAOMI
Participants in both treatment arms entered NAOMI
with the hope that they would be randomized to injectable
treatments. Their reasons for preferring the injectable
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ences with other addiction treatments, mainly oral metha-
done. Some participants described wishing to be part of
NAOMI to obtain “free heroin,” in the context of not hav-
ing to hustle for a period of time. Others expected that
NAOMI would alleviate financial distress, provide stabil-
ity, reduce involvement in sex work, and assist them with
improving their health and social situation.
It wasn’t about gettin’ high for me. It was about getting
a life… That’s why I had went in…It was about not
being sick. And, taking away that obsession…I wish I
was still in it. I do. [female non-Aboriginal participant,
age 50, DAM, nonresponder, retained]I could not manage, my pain, uh, when I first heard
about it [NAOMI]. I was, I was in, let’s say, [sigh]
medium, or, or, mild chronic pain. If, if, I did have a
round-the-clock pain, which happened quite often, it
would uh be kind of low level and could be treated
with drugs. But I just, [pause] I have a hard time stay-
ing on methadone. It doesn’t seem to do anything for
me and it doesn’t, doesn’t help the pain. Doesn’t, so
uh, yeah, so that’s, that, I’ve tried it a number of times.
And it just doesn’t seem to work for me. So I was hoping
that I would get randomized to be heroin…. And of
course I didn’t. [male non-Aboriginal participant, age
40, MMT, nonresponder, not retained]
Perceived impact of NAOMI treatment
Illicit drug use
Participants in both treatment arms (mainly injectable
participants) described a significant reduction in illicit heroin
use during NAOMI. Participants reflected that the reduction
in heroin use was due to the quality of the medication and
the consistency of the dose received in the clinic.
But I didn’t have any, uh physical need to, to do
heroin, outside of the programme. I didn’t, there was
enough dosage for me to uh, as long as I made the
sessions, I didn’t need. [male non-Aboriginal partici-
pant, age 50, DAM, responder, retained]
Some of these participants, including one oral partici-
pant, also said that they stopped using street heroin for
the entire time they were receiving study treatments.
Those receiving injectable treatment expressed their lack
of physical need or a desire to engage in ‘the hustle’ to
obtain illicit heroin.
I didn’t have to steal. I didn’t have to rob people. I
didn’t have to do things like that. My drugs were taken
care of. [male non-Aboriginal participant, age 40,
HDM, responder, retained]Few described occasional use of street heroin, mostly
due to continued use of ‘speedballs’ (i.e., injection of
cocaine and heroin) or simply due to curiosity.
I smoked rock [crack cocaine] every day. And, but uh,
heroin I did it, I bet you I could count on one hand the
amount, the times I did heroin during the whole
NAOMI thing. [female Aboriginal participant, age 50,
DAM, responder, retained]
In addition to heroin, crack cocaine was the most
common illicit substance discussed by participants. Dur-
ing NAOMI, the majority of participants (mostly those
receiving injectable treatment) indicated experiencing either
a decrease or no change to their crack cocaine use. Reasons
for reducing crack cocaine use varied; many participants
stated they were ‘tired, sick of it, realized what life was like
before they started doing drugs;’ one participant (DAM fe-
male, nonresponder, retained) stated that she reduced
crack cocaine use because she was not engaging in sex
work as often as before NAOMI.
A few participants reported an increase in crack cocaine,
and their discussions about this were more elaborate than
those who described no change or a reduction in crack co-
caine use. This increase was described by male partici-
pants only, regardless of randomization arm, response, or
retention to NAOMI treatment. Participants associated
their increased crack cocaine use with having more freed-
up funds and the ‘engrained’ lifestyle associated with daily
drug use. Other aspects of participants lives, such as the
environment in which participants lived, their relation-
ships, and their sources of income (i.e., drug dealing), were
described as challenges to completely stopping illicit drug
use.
Participant: And I just, you know, the financial, uh,
freedom from having to buy heroin every day. Like you
known more money in my pocket and, unfortunately,
rather than spend it um more um, sane fashion. I got
to uh, a lot of it went to uh, crack and cocaine.Interviewer: Right. So, do you think? How, how could
that be any different? Really, how, could NAOMI have
accommodated that or other treatment programmes in
the future?Participant: Um, it’s not easy. If it wasn’t in the
neighbourhood, you know. [male non-Aboriginal par-
ticipant, age 50, DAM, responder, retained]
Illicit activities
Prior to NAOMI treatment, participants discussed their
histories of engaging in drug dealing, petty theft, and sex
work (female participants only) as a means of supporting
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indicated no longer engaging in these activities, given
the provision of treatments in NAOMI.
I didn’t have to steal. I didn’t have to rob people. I
didn’t have to do things like that. My drugs were taken
care of. [male non-Aboriginal participant, age 40,
HDM, responder, retained]It got me out of the sex trade. The survival sex trade.
[female non-Aboriginal participant, age 50, DAM,
nonresponder, retained]
Housing
Housing situations varied considerably during the study.
Some participants said they were living in the same place
for years, others (mostly females) acquired housing dur-
ing NAOMI with the help of study staff, and two were
homeless at the time of the interview (both nonre-
sponders). Participants described how difficult it was to
acquire a secure place to live, expressing that they could
not afford decent places and needed to accept poor condi-
tions in order to have a place to live. Participants per-
ceived their drug use as a barrier to housing and believed
lack of housing was a barrier to work. Participants also
were not welcome at family or friends’ homes. Most of
those who were homeless for any period of time in their
life indicated that when they were clean, they found a
place to live (although the conditions were not always very
good due to the lack of affordable and liveable places).
I was only homeless, for I don’t know, 3 months or
something like that. I mean technically I’m homeless
right now, but I, I haven’t actually wound up on the
streets, you know. I got places to stay. And mean that’s
the thing. So when I went on the methadone, the need
for money isn’t as desperate. So um, I’m a little more
tolerable to be around, like I’m welcome at friend’s
houses and, to be at my dad’s house and stuff, because
I’m, you know. [pause] They’re not worried that I’m all
of a sudden start, [pause] start directly into, into
opiate withdrawal. And, crying, begging, for money.
[chuckle] kind of like that, right? so. It’s more relaxing
to be around me I suppose. [male non-Aboriginal
participant, age 40, MMT, responder, retained]
Health
At initiation to NAOMI, participants described having
both physical (i.e., infections, respiratory and dental prob-
lems) and mental health conditions (i.e., anxiety, depres-
sion, and suicidal ideation). Participants also described
suffering from chronic physical pain (e.g., arthritis, head-
aches, and injury-related pain) and emphasized that this
was one of the reasons for using illicit opioids and forseeking NAOMI treatment. Regardless of treatment arm,
response, and retention, participants experiencing mental
and physical health problems discussed how NAOMI’s
health care staff provided prescriptions for bipolar dis-
order and antiretroviral medications, as well as referrals
for acute and chronic conditions, such as arthritis, infec-
tions, and skin conditions.
And my health got pretty good too…Well, I’m HIV so, my,
uh, viral load went down. They [NAOMI doctors] were
[inaudible] I guess, yeah. I like ‘em. Well, some of the time
I went in there with injuries, so, so they took care of that
while I was there, you know? They knew about addiction
I guess, so, that was handy, yeah. [male Aboriginal
participant, age 40, DAM, responder, retained]
Overall impact of NAOMI
Overall, participants described a positive impact of the
study on their lives. There were only two negative com-
ments about the impact of NAOMI: randomization for
those assigned to oral and ending the study treatment
for those receiving injectable (described below in the
Ending NAOMI section). Participants in the oral group
articulated their disappointment with the outcome of
the randomization using expressions such as “disap-
pointed, devastated, bitter, went violent, wasn’t excited,
like a big bomb had dropped, I cried.” Some decided to
give oral methadone another try right away; others left
and eventually returned to treatment days or weeks later.
I came back about a month later and decided to go on
the methadone. […] Yeah the whole world just fell out
from beneath me when they said the word methadone.
[male, non-Aboriginal participant, age 40, MMT,
responder, retained]
Participants in both treatment arms (including nonre-
sponders) indicated that the treatments provided them
with stability, improved their sense of self-worth, strength-
ened their personal and community relationships, and
allowed them to reflect positively on their future.
And what the NAOMI project did for me was…let me
realize what my life was before I started doing drugs
and had to spend all my money on drugs and all my
free time, on getting money for drugs. And actually
made me realize like the other parts of my life, that I
had before, that I basically forgot about in the many
years that I was doing heroin. And right now, to this
day, I don’t do, any injection drugs at all…I feel a lot
better about myself too, like I have self-worth again.
And when I was an addict, doin’ dope, fuck I just, felt
dismal about myself. [male non-Aboriginal participant,
age 40, DAM, responder, retained]
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Interactions with health care providers
A common theme among participants in both treatment
arms was their interactions with health care staff at the
study clinic. Few participants described a negative inter-
action with health care staff. Participants were more de-
tailed during discussions about their interactions with
the physicians, but spoke positively about their general
interactions with health care staff. They described re-
ceiving care that was respectful, nonjudgmental, honest,
and felt the staff listened, really cared, understood, and
were always there to answer a question. The staff ’s experi-
ence and familiarity with the participants was beneficial
because staff were able to be proactive on addressing the
various needs of participants. For example, participants
discussed how the social workers helped address housing
and disability support needs.
When making comparisons between the quality of care
received at the study clinic with prior experiences in
community-based centers, participants in both treat-
ment arms emphasized their preference for the care at
NAOMI clinics because the physicians were more aware
of their needs, and they could be more open about ex-
pressing these needs.
Uh actually yeah he referred me to um to um what do
you call this? Um bone specialist…What do you call
this? Uh rheumatologist. He hooked me up with my
rheumatologist. Um at one point I had skin problem.
He got me an appointment with a skin specialist. I
mean he takes good care of me. And he explained to
me everything. He’ll turn his computer screen if I don’t
understand something and explain it to me. He, he’s
very good. I never, I never ran into a doctor like that
before in my life. [male non-Aboriginal participant,
age 40, MMT, nonresponder, retained]
Methadone maintenance treatment
Participants receiving oral treatment indicated they pre-
ferred the delivery of MMT at NAOMI clinics because
the services and staff were more easily accessible (i.e., no
wait times, pharmacy on site). A few participants also
expressed their preference for NAOMI’s titration protocol,
stating that the physicians increased doses in a manner
that was appropriate for the participant, allowing them to
reach a more stable and comfortable dose quickly. Partici-
pants suggested that being able to reach more satisfactory
doses and having a role in this decision was critical at the
beginning of treatment, as it reduced withdrawal symp-
toms and illicit heroin use.
I think the main thing is…Dr. XX put me up to, high
enough dose. Where I said before, I think I was on 80
before when I was at this other clinic. But I mean itwasn’t, it wasn’t enough. By the time I came to, it’s
quite a few hours before it came time to get my dose
for the next day. I was starting to, go through withdrawals.
And I was on methadone for like 2 months on that
dose and I was using all the time. And the doctor
wouldn’t put me up any more. [male, non-Aboriginal
participant, age 40, MMT, responder, retained]
In light of these positive experiences, the main recom-
mendation for improving oral treatment in NAOMI was
to extend the operating hours of the clinic.
Injectable treatments
Common topics about the logistics of treatment delivery
included lengthy pre- and post-assessment times, short
operating hours and lack of flexibility to accommodate
work schedules, and the overall amount of time spent at
the clinic. Males discussed the schedule, work, transportation,
and rules of the clinic.
And uh, I found it to uh, going three times a day was
almost, a full-time job…Cause I mean, three times, each,
each session you know? With travel time there and back
it, it took you know, like, you know, between five and six
hours a, a, day, right? And it’s basically impossible to uh,
try and go back to work. [male non-Aboriginal
participant, age 50, DAM, responder, retained]
Some participants, mostly female, discussed the adjust-
ment that was required for injecting in a supervised set-
ting, including changes to the routine (i.e., preparation
of own drug) and injection site (i.e., jugular, leg). An-
other complaint that a few participants discussed was
the time restriction set for the injection room (approxi-
mately 7 min). The reason for their difficulty with self-
administering the injectable medications was because of
poor vein health resulting from many years of injection
drug use.
It was hard for me because I’m not used to being around
people when I did mine, right. And it made me nervous
so I always had a hard time. [female Aboriginal
participant, age 50, HDM, responder, retained]Participant: Well, difficult, cause, um, being uh,
shooting dope for so long, and I don’t have any veins
left, so, the timeframe, and, uh, to hit being so large
uh, and in turkey baster syringe. and having a hard
time getting a vein, let alone in 7 minutes. And, I
ended up trying to, to do it intramuscularly, uh a lot
of times. [inaudible]Interviewer: Uh huh [affirmative] and did that change
your high then?
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you know, just, just takes a couple minutes and, to
kick in. [male non-Aboriginal participant, age 50,
DAM, responder, retained]
Participants also described the dose and quality of the
medications they were receiving in NAOMI as being sig-
nificantly better compared to street heroin. The im-
proved drug quality allowed them to worry less about
what other unknown substances they were inadvertently
taking.
Now, my first shot in NAOMI was 15 milligrams. The
effect I got off of that was damned close to the effect I got
off of shooting a quarter gram [of street heroin]…that’s
very drastic. And uh, it’s an eye opener, man…that
probably alone would have given me, reason enough to,
consider treatment of some kind. [male non-Aboriginal
participant, age 40, DAM, responder, retained]
Recommendations for improving the delivery of
injectable treatment
Logistics of the treatment were the most commonly refer-
enced recommendation for improving NAOMI. Partici-
pants suggested changes to the structure of the program,
including longer operating hours, more flexibility in ses-
sion times, and less time required for each visit. A few
male participants discussed the interference of the strict
schedule on their ability to work. Additional programs
were also a common recommendation, including voca-
tional and life skills support, as well as treatment for other
drug use. Although the treatment brought stability to par-
ticipants’ lives, there were concerns about how best to use
the time freed by the treatment.
If this was to ever get off the ground and be a
permanent thing, that something be implemented…to
take up this free time…maybe train for this or go to
school part-time or something just so you don’t have
all that time on your hands. [male Aboriginal
participant, age 51, DAM, responder, retained]
Participants also suggested that the treatments should
have been provided for a longer period of time, or tran-
sitioned into a program, in order to enhance and sustain
the benefits of the treatments.
Because by the time it was over that was when I really
felt that I was starting to stabilize, you know… on my
lifestyle… But if I’d had more time, maybe I would
have been able to…go another couple of routes, like,
uh, think about school or maybe even a job. But…it
was over a little too quick for that. [male Aboriginal
participant, age 40, DAM, responder, retained]Ending NAOMI
Participants receiving injectable treatment primarily
discussed the process and emotions of ending NAOMI.
Many study participants reported that they were able
to transition or continue on MMT with their NAOMI
study physician, either at the site of NAOMI or in
community-based clinics. A few refused MMT because
it did not work for them or because of unsuccessful
transitions (e.g., disagreements with health care provider).
Some participants receiving injectable treatments discussed
how NAOMI enabled them to consider engaging in
other treatment options (i.e., detox, MMT) that previously
would not have been considered.
Well, you know one of the effects of NAOMI and
I’m not sure how or why, I am more accepting of
methadone now than I was before. More able to,
uh you know, to accept, the reality of it. You know,
uh [pause] I’m not using as much opiates as I did
before, uh, at NAOMI, you know? And I, I don’t,
run to find opiates as quickly as I used to. [male
non-Aboriginal participant, age 51, DAM,
responder, retained]
Participants indicated that even though they under-
stood that injectable treatments were not guaranteed be-
yond the end of the study, they experienced anxiety, fear,
sadness, and stress due to ending the study.
And I was never under any illusions. And you
know, again, on the street people would say, yeah,
but what are you gonna do when it’s over? What I
would do the same as I did before. When it’s over.
You know, it’s a respite. It’s a gift. And I’m not
gonna sit here and complain about it. [male non-
Aboriginal participant, age 51, DAM, responder,
retained]
Participants remained hopeful that the evidence from
NAOMI would expand treatment options in Canada, and
they were happy to have been part of the study. None of
the interviewed participants expressed regret at being part
of NAOMI.
I was happy to be part of it…it gave me a bit of hope
into the future of um, addictions treatment in […]
Canada. Um, [pause]…there was an adjustment
period, when I got out of NAOMI there. I was sad.
And I was depressed for a little while, because you
know, when you have something like that comes to an
end, not only did I really miss the comfort and the
attention and the really caring staff, which I do still
miss. [male non-Aboriginal participant, age 40, DAM,
responder, retained]
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The aim of this study was to explore how participants in
the Canadian clinical trial testing injectable opioids per-
ceived the treatment received. The participants’ perspec-
tives of treatment with medically prescribed DAM were
concordant with the rationale of this model of care: by
providing pharmaceutical-grade heroin in a supervised
health care setting that also provided comprehensive
health services, we engaged street heroin-injecting indi-
viduals to treatment and offered them an opportunity to
reduce harms and illegal activities and improve their
health.
A prior study showed that participants in NAOMI ap-
plied to the clinical trial mainly to receive “free heroin”
[33]. In this study, the participants signified the possibil-
ity of receiving free heroin as an opportunity for getting
their lives back. The provision of medically prescribed
injectable opioids is described as introducing stability in
their lives. Now that the substance they were dependent
on was taken care of, there was no need to be involved
in illicit activities or sex work and they could direct their
resources to finding housing and possibly employment.
Also, through the daily contact with health care workers,
they were diagnosed and treated for other comorbidities.
This study provides an explanation as to why this treat-
ment is so effective, despite the strict regimen of the su-
pervised delivery model [14]. While participants discussed
the challenges associated with the logistics of treatment
delivery (e.g., schedules, no take-homes, injecting among
strangers), it does not reflect the emotions and intensity in
the way they described their lives while they were un-
treated: waking up in a panic, stealing, feeling hopeless,
depressed, and like a “total wreck.” The discourses re-
corded in this study suggest that participants found the
supervised delivery model stringent, but they highly val-
ued the stability it brought to their lives. This stability is
described mostly in relation to the provision of the inject-
able medications they considered beneficial, but also in
the supportive model of care. These results are consistent
with the findings of the Dutch and Andalusian reports on
participants’ perceptions of this treatment [20,21]. For ex-
ample, in the Dutch study, participants complained about
how the tight clinic schedules interfered with their daily
activities, such as household activities or work. However,
this schedule also provided structure to their lives, mostly
among those engaged in street activities, such as sex work
or drug dealing [21].
This study shows that the treatment provided was
considered effective at stopping the use of illicit opioids,
confirming our prior results [12]. As expected, partici-
pants receiving injectable opioids at the clinic reported
not using street opioids. As in prior studies [19-21], our
data show that the secure drug supply translated into a
significant decrease of engagement in illicit activities andthe daily street hustle. This release of time, and in some
cases resources, introduces an important challenge for
patients and the community: how to fill this free time.
For example, participants in the Andalusian study con-
veyed the challenge of suddenly not having to spend the
day going after heroin and how their needs beyond her-
oin became evident, such as lack of skills to obtain em-
ployment [22]. Results from the parent trial found no
changes in the use of cocaine from baseline [12], and ac-
cordingly, in this study most of the participants reported
having reduced or not changed their cocaine use. How-
ever, those few whose cocaine use increased attributed it
to having more funds available and their struggle to dis-
engage from the drug scene.
In NAOMI’s analysis of satisfaction with treatment,
after controlling for treatment effectiveness, those ran-
domized to the injection group were significantly more
satisfied with treatment than those in the MMT group
[18]. From the open-ended comments section of the
Client Satisfaction Questionnaire, participants in both
arms of the study described the need for additional an-
cillary and nutritional services. The present findings
confirm this, with participants expressing that voca-
tional and skills training would be beneficial programs
as participants begin to experience stability in their
lives and are confronted with the need to plan for their
future.
The gender-based analysis in the NAOMI study found
that retention and clinical response to DAM treatment
were slightly lower among women than men (though
not statistically significant) [34]. In the qualitative analysis,
men and women had similar discourses, except women
discussed the adjustment required for the environment
and physical site of injectable treatment administration
(e.g., the public environment of the injection room),
whereas males focused on the challenging schedule of
the treatment and its impact on their ability to work.
Women’s experiences with the logistics of the clinical
care setting may explain the slightly reduced retention
and response rates.
Some participants (mainly male) were concerned
about the schedule of the treatment and its impact on
their ability to work. The potential impact on the cap-
acity for employment of coming to a clinic two to three
times per day has been raised as an issue of this treat-
ment model [35]. However, there are many alternatives
under this model that would facilitate patients adjust-
ing to a work schedule. For example, clinics in Europe
offer a combination of injectable and oral long-acting
opioids (e.g., methadone), and have diversified options
(e.g., methadone, morphine, DAM, etc.) for managing
individual patient needs [36]. Also, several studies show
that after a period of stabilization some patients voluntar-
ily transition to oral methadone or abstinence-oriented
Oviedo-Joekes et al. Addiction Science & Clinical Practice 2014, 9:21 Page 9 of 10
http://www.ascpjournal.org/content/9/1/21treatment [37,38], options that allow a schedule more
amenable to work.
Due to clinic capacity, participants entered the trial on
a staggered schedule to complete the planned sample
size over time. The last participants finished the treat-
ment in April and June 2008, respectively, in Vancouver
and Montreal. This study collected data between February
and September 2008. Participants expressed their absolute
disappointment with the end of the injectable treatments
and explained the negative impact on their lives. Regard-
less, they saw the NAOMI experience as a positive one.
They referenced mostly two aspects: First, for a period of
time, they obtained stability and had the chance to make
plans beyond how to obtain the drug. Second, they had
the hope that NAOMI would become a program and were
proud of having helped to build evidence for this case.
This study provides further explanation of why treat-
ment with injectable DAM, despite the supervised model
of care, can be effective. Our evidence adds to the current
(and limited) data on participant perceptions of treatment
with injectable DAM for long-term opioid dependence.
Such data are particularly useful as future programs
with this treatment are developed. Patient engagement
in chronic disease treatment is essential to promoting
treatment access and retention, thus reducing the bur-
den of disease for the individual and society.
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